ALK

What ALK does

ALK-Abelló A/S is a Danish specialty pharmaceutical company founded in 1923 and headquartered in Hørsholm, Denmark, focused on the prevention, diagnosis, and treatment of allergies — particularly respiratory allergies such as hay fever, allergic rhinitis, and allergic asthma. The company develops and manufactures allergy immunotherapy (AIT) products derived from natural allergens (grass pollen, birch and related trees, house dust mites) using standardized extracts that the firm has refined since introducing the industry's first standardized process in 1972. Its commercial portfolio includes sublingual immunotherapy tablets (GRAZAX® for grass pollen, ACARIZAX® for house dust mite allergy, ITULAZAX® for tree pollen), subcutaneous injection therapies (Alutard SQ, Aquagen SQ), the Jext® adrenaline auto-injector for anaphylaxis, and Soluprick SQ® diagnostic extracts, plus the klarify.me digital patient-guidance platform launched in 2018.

The business operates globally with ~2,500–2,800 employees, four active pharmaceutical ingredient production sites (Denmark, Spain, France, USA), and a commercial footprint spanning 46 markets through direct subsidiaries and regional distribution partnerships (Torii for Japan, Abbott for Russia/Southeast Asia, Seqirus for Australia/New Zealand). Approximately 1.5 million patients worldwide are on ALK treatments. Revenue is generated primarily through prescription pharmaceutical sales distributed via physicians, pharmacies, and national health systems, paid for by healthcare insurers and government payers; the company is listed on NASDAQ Copenhagen (ticker: ALK B) with Lundbeckfonden as controlling shareholder (67% of votes, 40% of capital). Go-to-market is sales-led, relying on medical representatives, healthcare-professional education programs (e.g., 'Talk by ALK', SOSA symposium), and prescriber-facing digital portals (ALK Pro Global).

The company's go-to-market emphasizes disease-modifying therapy rather than symptomatic relief: AIT retraining of the immune system over 3–5 year courses, with clinical evidence from the GAP study — the world's largest pediatric allergy vaccination trial — demonstrating reduced asthma development risk and durable post-treatment effect. Pipeline activity targets expansion to ragweed and Japanese cedar allergies, reinforcing ALK's positioning as the long-standing global leader in prescription allergy immunotherapy.

Name

ALK

Legal name

ALK-Abelló A/S

Website

https://alk.dk

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ALK-Abelló A/S is a Danish specialty pharmaceutical company developing and selling prescription allergy immunotherapy (AIT) products — sublingual tablets, subcutaneous injections, diagnostics, and adrenaline auto-injectors — to treat the underlying cause of respiratory allergies across 46 markets for roughly 1.5 million patients.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

• Allergy immunotherapy products
• Sublingual immunotherapy tablets
• Allergy vaccination treatments
• Respiratory allergy medicines
• Allergen diagnostics extracts

Headquarters

HQ city

Hørsholm

HQ country

Denmark

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Prescription Allergy Immunotherapy Products: ALK generates revenue through prescription pharmaceutical products including sublingual immunotherapy tablets (GRAZAX, ITULAZAX, ACARIZAX), injection-based immunotherapy (Alutard SQ, Aquagen SQ), adrenaline auto-injectors (Jext), and allergy diagnostics (Soluprick SQ). Revenue is generated through prescription sales primarily via healthcare systems and pharmacies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ALK develops, manufactures, and commercializes pharmaceutical products for allergy prevention, diagnosis, and treatment. Its portfolio centers on allergy immunotherapy (AIT) — including sublingual tablets (GRAZAX, ACARIZAX, ITULAZAX), subcutaneous injections (Alutard SQ, Aquagen SQ), adrenaline auto-injectors (Jext), and skin prick diagnostics (Soluprick SQ) — that treat the underlying cause of allergy rather than just symptoms.

Product overview

ALK is a global specialty pharmaceutical company focused on allergy treatment and prevention. The company offers a comprehensive portfolio centered on allergy immunotherapy (AIT) - treatments that address the underlying cause of allergy rather than just relieving symptoms. The core product portfolio includes GRAZAX® (grass pollen sublingual tablet), ACARIZAX® (house dust mite sublingual tablet), and ITULAZAX® (tree pollen sublingual tablet) for sublingual immunotherapy; Alutard SQ and Aquagen SQ for subcutaneous immunotherapy injections; Jext® adrenaline auto-injectors for anaphylaxis emergency treatment; and Soluprick SQ® for allergy diagnostics. ALK's approach treats the root cause of allergy through long-term immunotherapy lasting 3-5 years, which reprograms the immune system to build tolerance to specific allergens. The company also offers digital support through its klarify.me platform.

Differentiator

Problem solved

Functional benefit

Products and services

• GRAZAX® Sublingual allergy immunotherapy tablet for grass pollen allergy. It is the only grass pollen immunotherapy tablet approved as a disease-modifying treatment that modifies the underlying cause of allergy rather than just relieving symptoms.
• ACARIZAX® Sublingual allergy immunotherapy tablet for house dust mite allergy. Approved for treatment of both hay fever and allergic asthma caused by house dust mite allergy.
• ITULAZAX® Sublingual allergy immunotherapy tablet for tree pollen (birch and related tree species) allergy. Approved for treatment of hay fever in adults.
• Jext® Adrenaline auto-injector for emergency treatment of severe allergic reactions (anaphylaxis). Provides rapid intramuscular injection of adrenaline.
• Soluprick SQ® Standardized allergy diagnostic extract for skin prick testing. Used to diagnose allergies by applying allergen extracts to the skin and observing reactions.
• Alutard SQ Subcutaneous allergy immunotherapy injection for treatment of various respiratory allergies including grass pollen, tree pollen, house dust mite, and venom allergies.
• Aquagen SQ Aqueous allergy immunotherapy injection solution for subcutaneous administration in allergy treatment.
• klarify.me Digital platform launched in 2018 offering a range of digital resources to guide people with allergies to appropriate help, including information and self-assessment tools.

Quantifiable outcome

• World's largest clinical study on allergy vaccination in children (GAP study) showed significant reduction in asthma symptoms in children treated with GRAZAX
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ToriicoreChannel Partner/ Reseller/ DistributorPartnership with Torii for marketing allergy vaccination tablets in Japan, one of the key markets for ALK's international expansion.
• AbbottcoreChannel Partner/ Reseller/ DistributorPartnership with Abbott for marketing allergy vaccination products in Russia and Southeast Asia.
• SeqiruscoreChannel Partner/ Reseller/ DistributorPartnership with Seqirus for marketing allergy vaccination tablets in Australia and New Zealand.
• Ernst & Young Global LimitedminorOthersExternal consulting firm engaged for regulatory and policy dialogue activities.
• LEAD Agency A/SminorOthersExternal consulting firm engaged for regulatory and policy dialogue activities.
• Rud Petersen A/SminorOthersExternal consulting firm engaged for regulatory and policy dialogue activities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• LETI Pharma: Spanish specialty pharmaceutical company focused on allergy immunotherapy and diagnostics. Comparable as a smaller AIT specialist with overlapping SLIT/SCIT and skin-testing product lines.
• HAL Allergy: European allergen immunotherapy manufacturer offering diagnostic and therapeutic allergy products. Comparable as a regional AIT specialist competing with ALK across SLIT, SCIT, and diagnostics.
• Allergy Therapeutics: UK-based specialty pharma developing and commercializing allergy immunotherapy vaccines (SCIT and SLIT). Comparable product portfolio, target indications, and patient population to ALK's AIT franchise.
• Stallergenes Greer: A global specialty immunotherapy company focused on allergy diagnosis and treatment via SCIT and SLIT products. Directly comparable as ALK's closest pure-play competitor in allergen-specific immunotherapy.
• Merck KGaA (Allergopharma): Operates the Allergopharma business manufacturing and marketing allergen immunotherapy products for diagnosis and treatment. Directly comparable therapeutic focus and SLIT/SCIT offerings to ALK.

Emerging players

• DBV Technologies: Clinical-stage biotech developing epicutaneous immunotherapy (Viaskin patch) for food and respiratory allergies. Comparable as an emerging AIT modality competitor pursuing disease-modifying allergy treatment.

Broad incumbents

• Teva Pharmaceutical Industries: Major generics and specialty pharma with respiratory products including allergy medications and EpiPen competitor products. Comparable as a broad player in allergy medication and emergency epinephrine delivery.
• GSK: Global pharmaceutical company with respiratory/allergy franchises including inhaled corticosteroids, antihistamines, and the Nucala biologic. Comparable as a broad incumbent in respiratory and allergic disease treatment.
• Sanofi: Major diversified pharma with allergy and respiratory offerings including antihistamines (e.g., Allegra/Xyzal) and biologic asthma therapies (Dupixent). Comparable as a broad incumbent competing across the allergy treatment continuum.
• Regeneron: Develops and commercializes Dupixent (dupilumab) in collaboration with Sanofi for allergic asthma, CRSwNP, and atopic dermatitis. Comparable as a competing therapeutic modality for moderate-to-severe allergic disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALK